FRONTEO and Otsuka Holdings announced a joint project to accelerate drug discovery in the renal field with AI. The two companies aim to pursue joint innovation through an AI Factory.
FRONTEO and Otsuka Holdings announced that they will begin collaborating on drug discovery in the renal field. Details of the specific research activities and target diseases will be provided in subsequent disclosures.
The two companies indicated that they plan to establish and operate an AI Factory as a framework for supporting drug discovery centered on AI technology, with the aim of improving the efficiency of the search for and evaluation of drug candidates.
The collaboration seeks to accelerate the drug discovery process through the sharing of data and insights, and is intended to generate new findings that contribute to the development of therapeutic drugs.
Going forward, the companies are expected to disclose specific development schedules and performance indicators.